Axcelis Technologies, Inc. $ACLS Shares Sold by Boston Trust Walden Corp

Key Points

• Boston Trust Walden cut its Axcelis Technologies stake by 5.2% in the third quarter, selling 18,837 shares; it retained 340,419 shares worth about $44.7 million.
• Analyst sentiment is mixed but averages to Hold: one analyst rates ACLS Buy, three Hold and one Sell, with an average price target of $148.67.
• Axcelis beat quarterly estimates, reporting EPS of $1.06 versus $0.89 expected and revenue of $215.18 million versus $205.03 million expected; revenue grew 10.6% year over year.

Boston Trust Walden Corp trimmed its holdings in Axcelis Technologies, Inc. (NASDAQ:ACLS - Free Report) by 5.2% in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 340,419 shares of the semiconductor company's stock after selling 18,837 shares during the quarter. Boston Trust Walden Corp owned about 1.10% of Axcelis Technologies worth $44,656,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of ACLS. Public Employees Retirement System of Ohio bought a new position in Axcelis Technologies in the second quarter worth approximately $82,000. Ancora Advisors LLC purchased a new stake in Axcelis Technologies in the second quarter worth about $95,000. NewEdge Advisors LLC raised its stake in shares of Axcelis Technologies by 247.9% in the second quarter. NewEdge Advisors LLC now owns 581 shares of the semiconductor company's stock worth $110,000 after buying an additional 414 shares during the period. MassMutual Private Wealth & Trust FSB lifted its position in shares of Axcelis Technologies by 25.9% during the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 598 shares of the semiconductor company's stock valued at $78,000 after buying an additional 123 shares in the last quarter. Finally, Parallel Advisors LLC lifted its position in shares of Axcelis Technologies by 22.0% during the 1st quarter. Parallel Advisors LLC now owns 665 shares of the semiconductor company's stock valued at $62,000 after buying an additional 120 shares in the last quarter. Hedge funds and other institutional investors own 89.98% of the company's stock.

Analyst Upgrades and Downgrades

ACLS has been the topic of several research analyst reports. Weiss Ratings upgraded Axcelis Technologies from a "hold (c-)" rating to a "hold (c)" rating in a research report on Friday, October 16th. Craig Hallum downgraded Axcelis Technologies from a "buy" rating to a "hold" rating and set a $140.00 target price on the stock. in a research note on Friday, August 7th. One investment analyst has rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Axcelis Technologies currently has an average rating of "Hold" and an average target price of $148.67.

Axcelis Technologies Stock Performance

Shares of ACLS opened at $92.14 on Thursday. Axcelis Technologies, Inc. has a 12 month low of $73.60 and a 12 month high of $193.78. The stock has a fifty day moving average price of $116.69 and a 200-day moving average price of $122.67. The company has a current ratio of 4.90, a quick ratio of 3.21 and a debt-to-equity ratio of 0.04. The firm has a market cap of $2.85 billion, a PE ratio of 24.91, a P/E/G ratio of 2.97 and a beta of 1.88.

Axcelis Technologies (NASDAQ:ACLS - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The semiconductor company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.89 by $0.17. The company had revenue of $215.18 million for the quarter, compared to analyst estimates of $205.03 million. Axcelis Technologies had a net margin of 10.71% and a return on equity of 11.69%. The firm's revenue was up 10.6% on a year-over-year basis. During the same period in the prior year, the company earned $1.13 earnings per share. Equities research analysts predict that Axcelis Technologies, Inc. will post 3.39 earnings per share for the current fiscal year.

Axcelis Technologies Profile

Axcelis Technologies, Inc develops and manufactures equipment used in the fabrication of semiconductor devices. The company is best known for its ion implantation systems, which precisely introduce dopant atoms into silicon wafers to control the electrical properties of semiconductor components.

Its product portfolio includes the Purion family of ion implantation systems, designed for applications such as high-current, medium-current and high-energy implantation. Axcelis also provides related aftermarket products and services, including spare parts, equipment upgrades, process support and customer training.

Headquartered in Beverly, Massachusetts, Axcelis serves semiconductor manufacturers and other customers in major chip-production regions worldwide.

Want to see what other hedge funds are holding ACLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axcelis Technologies, Inc. (NASDAQ:ACLS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.